23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

Me (ME) ended December 31, 2024 with cash and cash equivalents of $79.4M, compared to $126.6M as of September 30, 2024 and $216.5M as of ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...

Are you also related to Charlemagne, described as 'one of the most important people in history'? Well, according to scientists, it's not difficult to find out.

Advances in DNA technology in the past three decades led Everett police to a Las Vegas man who was Maryann Daniels' neighbor when she was killed in 1989.

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...